Shanghai Pharmaceuticals (601607.SH): Pyridostigmine Bromide Sustained-Release Tablets Approved for Production

Stock News10-28

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. ("Shangyao Zhongxi"), recently received the "Drug Registration Certificate" (Certificate No.: 2025S03175) from the National Medical Products Administration (NMPA) for Pyridostigmine Bromide Sustained-Release Tablets, approving its production.

Pyridostigmine Bromide Sustained-Release Tablets are used to treat myasthenia gravis and were originally developed by BAUSCH, first approved in the U.S. in 1959. In March 2024, Shangyao Zhongxi submitted a registration application for the drug to the NMPA, which was subsequently accepted.

As of the announcement date, the company has invested approximately RMB 16.009 million in R&D for this drug. Currently, no other domestic manufacturers have launched Pyridostigmine Bromide Sustained-Release Tablets in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187578498?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 15:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187578498","market":"other","top_or_hot":-1,"title":"Shanghai Pharmaceuticals (601607.SH): Pyridostigmine Bromide Sustained-Release Tablets Approved for Production","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received the \"Drug Registration Certificate\" (Certificate No.: 2025S03175) from the National Medical Products Administration (NMPA) for Pyridostigmine Bromide Sustained-Release Tablets, approving its production.</p>\n<p>Pyridostigmine Bromide Sustained-Release Tablets are used to treat myasthenia gravis and were originally developed by BAUSCH, first approved in the U.S. in 1959. In March 2024, Shangyao Zhongxi submitted a registration application for the drug to the NMPA, which was subsequently accepted.</p>\n<p>As of the announcement date, the company has invested approximately RMB 16.009 million in R&D for this drug. Currently, no other domestic manufacturers have launched Pyridostigmine Bromide Sustained-Release Tablets in China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals (601607.SH): Pyridostigmine Bromide Sustained-Release Tablets Approved for Production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals (601607.SH): Pyridostigmine Bromide Sustained-Release Tablets Approved for Production\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-28 15:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received the \"Drug Registration Certificate\" (Certificate No.: 2025S03175) from the National Medical Products Administration (NMPA) for Pyridostigmine Bromide Sustained-Release Tablets, approving its production.</p>\n<p>Pyridostigmine Bromide Sustained-Release Tablets are used to treat myasthenia gravis and were originally developed by BAUSCH, first approved in the U.S. in 1959. In March 2024, Shangyao Zhongxi submitted a registration application for the drug to the NMPA, which was subsequently accepted.</p>\n<p>As of the announcement date, the company has invested approximately RMB 16.009 million in R&D for this drug. Currently, no other domestic manufacturers have launched Pyridostigmine Bromide Sustained-Release Tablets in China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"","article_id":"1187578498","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187578498","pubTimestamp":1761637218,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received the \"Drug Registration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0196":"行业龙头","BK0028":"国家队","BK0187":"一线龙头","BK0184":"上海国资改革","BK0175":"白马股","BK0097":"医药电商","BK0099":"上海本地重组","BK1197":"保健护理产品经销商","BK0020":"浦东新区","02607":"上海医药","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"上海医药（601607.SH）：溴化吡啶斯的明缓释片获批生产","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. (\"Shangyao Zhongxi\"), recently received the \"Drug Registration Certificate\" (Certificate No.: 2025S03175) from the National Medical Products Administration (NMPA) for Pyridostigmine Bromide Sustained-Release Tablets, approving its production.\nPyridostigmine Bromide Sustained-Release Tablets are used to treat myasthenia gravis and were originally developed by BAUSCH, first approved in the U.S. in 1959. In March 2024, Shangyao Zhongxi submitted a registration application for the drug to the NMPA, which was subsequently accepted.\nAs of the announcement date, the company has invested approximately RMB 16.009 million in R&D for this drug. Currently, no other domestic manufacturers have launched Pyridostigmine Bromide Sustained-Release Tablets in China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187578498","isCrawlerRequest":true}